期刊文献+

反相高效液相层析法测定血浆中氯雷他定浓度及药动学研究

Determination of plasma loratadine concentration with RP-HPLC and its pharmacokinetic study
下载PDF
导出
摘要 目的:建立测定血浆中氯雷他定浓度的反相高效液相层析方法,并对其在人体内的药动学进行研究.方法:血浆中氯雷他定用正己烷-甲基叔丁基醚(1:1)作液-液萃取挥干后,加流动相进样分析.反相高效液相层析方法采用Hypersil-BDS层析柱,流动相为乙腈-水(65:35,磷酸调pH 3.8),流速1.0 ml/min;紫外检测波长为248 nm.结果:氯雷他定在0.506 0~50.60 ng/ml血浆浓度范围内线性良好(r=0.999 5),平均相对回收率>95.0%,日间和日内RSD<15.0%.主要药代动力学参数:t1/2为(1.57±0.18)h;MRT为(2.46±0.19)h;Cl/F为(583.7±215.0)L/h cmax为(37.40±8.92)ng/ml;tmax为(1.0±0.20)h;AUC0~8 h为(73.24±21.30)ng·h/ml AUC0~∞为(75.57±21.70)ng·h/ml.结论:该方法操作方便,结果准确,可用于血浆中氯雷他定药代动力学研究. Objective : To establish a RP-HPLC method for the determination and pharmacokinetic study of loratadine in Chinese healthy volunteers. Methods; Chrornatography was performed on a Hypersil-BDS with acetonitrile-water (65 : 35, pH was adjusted to 3. 8 with H3PO4) as mobile phase. The flow rate was 1. 0 ml/min and the UV wavelength was set at 248 nm. Results: Good linearity was found within 0. 506 0-50. 60 ng/ml of loratadine in human plasma(r = 0. 999 5). The mean relative recovery rate was more than 95% ; intra-day and inter-day RSD were less than 15. 0%. The limit of detection was 0. 506 ng/ml. The main pharmacokinetic parameters were as follows:t12 was (1. 57 ± 0. 18) h;MRT was (2. 46±0. 19) h;Cl/ F was (583. 7±215. 0) L/h;cmax, was (37. 40±8. 92) ng/ml;tmax was (1. 0±0. 20) h;AUC0-8h was (73. 24±21. 30) ng · h/ ml;.AUC/C0-∞ was (75. 57±21. 70) ng · h/ml. Conclusion: Our method has a good selectivity and sensitivity and can be used for further clinical pharmacokinetic study of loratadine.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2004年第5期570-571,共2页 Academic Journal of Second Military Medical University
关键词 反相高效液相层析法 测定 血浆 氯雷他定 浓度 药代动力学 loratadine pharmacokinetics chromatography, high pressure liquid
  • 相关文献

参考文献6

二级参考文献7

  • 1Pawel K Kunicki. Determination of loratadine in human plasma by high- perforrnanee liquid chromatographic method with ultraviolet detection[ J ]. Journal of Chromatography B, 755(2001):331 - 335.
  • 2James Hilbert, Elaine Radwanski, Bay Weglein, et al.Pharmacokinetic and dose proportionality of loratadine [ J ]. J Clin Pharmacol, 1987 ;27:694 - 698.
  • 3R. L. Batenhorst,A. S. Batenhorst,D. A. Graves,T. S. Foster,M. Kung,R. P. Gural,H. J. Amkraut. Pharmacologic evaluation of loratadine (SCH 29851), chlorpheniramine and placebo[J] 1986,European Journal of Clinical Pharmacology(2):247~250
  • 4A. Barnett,L. C. Iorio,W. Kreutner,S. Tozzi,H. S. AnH,A. Gulbenkian. Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine[J] 1984,Agents and Actions(5-6):590~597
  • 5江志强,蒋新国,奚念朱,陈桂良,刘倩,张顺妹.氯雷他定血药浓度HPLC测定方法建立和生物利用度[J].中国药学杂志,1999,34(11):757-759. 被引量:22
  • 6钟国平,王雪丁,黄丽慧,曾桂雄,汤琤,黄民,张选红.氯雷他定片在健康志愿者的药代动力学与生物等效性研究[J].中国临床药理学杂志,2002,18(2):105-108. 被引量:18
  • 7阮邹荣,袁虹,孙凌.反相高效液相色谱法测定人血浆中氯雷他定浓度[J].药物分析杂志,2002,22(4):296-298. 被引量:11

共引文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部